]>
IRCT20170606034348N3 IRCT 2019-04-11 Babol University of Medical Sciences Effect of memantin on cognitive performance in patient under electroconvolsive therpy (clinical trial) ect Effect of memantin on cognitive performance in patient under electroconvolsive therpy (clinical trial) 2018-05-22 anticipated 60 Complete https://irct.ir/trial/38633 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: , Randomization description: In this study, a random number randomization tool was used, Blinding description: After initial examination, ECT candidates are randomly divided into control and case groups. Patients in the memantine group and patients in the placebo control group are capsules that are filled with ointment and placed in the memantine pill inside the capsule and divided into two groups A and B. None of the patients, researcher or analyst will know the grouping of the groups, and the third partner is aware of the division of A and B, and at the end of the work the groups receiving the placebo and the drug will be identified. 1-2 Cognitive impairment. Control group: Control group: Memantine in the case group starts 24 hours before the start of the study with a dose of 10 mg and will increase to 20 mg in a week. And will continue until the end of session 6 of the ECT. The placebo control group will be given. The cognitive ability of the patients will be measured 24 hours before and 24 hours after the ECT session 6, as well as one month after the ECT atomic, using the MMSE (Mini Mental Status Examination) and the Aden Brook Cognitive Examination Test. We will use the MMSE Iranian version in this study.. Yes - There is a plan to make this available What will be shared: abstract Full article file When: Start the access period 6 months after printing the results To whom: Researchers working in academia and academia or those working in the industry can apply for them Conditions: Maintaining a moral charter Refer to the present article in their project Where to obtain: Babol university of medical science Yahyanejad hospital Angela Hamidia MD How to obtain: access period 6 months after printing the results Researchers working in academia and academia Comments:
public Dr. Angela Hamidia
Khomeyni Ave, Yahyanejad hospital
Babol Iran (Islamic Republic of) 4713566547 +98 11 3219 9596 a.hamidia@mubabol.ac.ir Babol University of Medical Sciences scientific Angela Hamidia
khomeini Ave, Yahyanejad Hospital
babol Iran (Islamic Republic of) 4713566547 +98 11 3129 9596 a.hamidia@mubabol.ac.ir Babol University of Medical Sciences Iran (Islamic Republic of) In this clinical trial, 60 patients over the age of 18 and under the age of 60 with bipolar disorder psychiatric illnesses will be admitted to the ECT since the beginning of the year 1396-97.All patients will undergo a full psychiatric assessment and patient disorder is recorded based on DSM-V. 18 years 60 years Both Age outcomes aged less than 18 years and over 60 years of age, alcohol dependence or drug and drug addiction (except nicotine and caffeine) within 3 months of admission, confirmed kidney disease, epilepsy, back Mental retardation, cognitive impairments such as delirium and dementia, history of memantine use in the past 3 months before entering the study, patients who are unable to perform tests due to distraction , gastrointestinal disturbances and memantine susceptibility, and during Studying or suffering from intolerance to increasing the dose of memantine, as well as patients who receive more than 6 ECT sessions, are excluded be. Placebo Control group: Control group: Memantine in the case group starts 24 hours before the start of the study with a dose of 10 mg and will increase to 20 mg in a week. And will continue until the end of session 6 of the ECT. The placebo control group will be given. The cognitive ability of the patients will be measured 24 hours before and 24 hours after the ECT session 6, as well as one month after the ECT atomic, using the MMSE (Mini Mental Status Examination) and the Aden Brook Cognitive Examination Test. We will use the MMSE Iranian version in this study. The cognitive ability of the patients will be measured 24 hours before and 24 hours after the ECT session 6, as well as one month after the completion of the ECT using the MMSE (Mini Mental Status Examination) and the Aden Brook Cognitive Examination Test. We will use the MMSE Iranian version in this study. Timepoint: 24 hours before and 24 hours after the 6th session of the ECT, as well as one month after the completion of the ECT. Method of measurement: Eden Brook MMSE (Mini Mental Status Examination). As well as one month after the completion of the ECT using the MMSE (Mini Mental Status Examination) and the Aden Brook Cognitive Examination Test. We will use the MMSE Iranian version in this study. Timepoint: One month after the completion of the ECT. Method of measurement: In this research we will use the Iranian version of MMSE and Eden Brooke. Babol University of Medical Sciences Approved 2019-03-10 Babol University of Medical Sciences Keshavarz Boulevard babol Mazandaran Iran (Islamic Republic of)